Entia Biosciences, Inc.
ERGO
$0.0001
-$0.0001-50.00%
| Weiss Ratings | ERGO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | ERGO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | ERGO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -117.56 | |||
| Price History | ERGO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | 0.00% | |||
| 60-Day Total Return | -50.00% | |||
| 90-Day Total Return | -50.00% | |||
| Year to Date Total Return | -50.00% | |||
| 1-Year Total Return | 0.00% | |||
| 2-Year Total Return | -66.67% | |||
| 3-Year Total Return | -99.80% | |||
| 5-Year Total Return | -98.46% | |||
| 52-Week High % Change | -50.00% | |||
| 52-Week Low % Change | 9,900.00% | |||
| Price | ERGO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.00 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Jul 15, 2024 | |||
| 52-Week High Price (Date) | Sep 10, 2024 | |||
| Valuation | ERGO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 3.41K | |||
| Enterprise Value | -- | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -- | |||
| Earnings Per Share Growth | -- | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -- | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.00 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -- | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | ERGO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | -- | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ERGO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 971-228-0709 | |||
| Address | 13565 SW Tualatin-Sherwood Road Sherwood, OR 97140 | |||
| Website | www.entiabio.com | |||
| Country | United States | |||
| Year Founded | 2007 | |||
| Profitability | ERGO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -439.66% | |||
| Profit Margin | -525.72% | |||
| Management Effectiveness | ERGO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -164.37% | |||
| Return on Equity | -- | |||
| Income Statement | ERGO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 265.50K | |||
| Total Revenue (TTM) | 265.50K | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | 173.90K | |||
| EBITDA (TTM) | -1.15M | |||
| EBIT (TTM) | -1.17M | |||
| Net Income (TTM) | -1.40M | |||
| Net Income Avl. to Common (TTM) | -1.40M | |||
| Total Revenue Growth (Q YOY) | -32.75% | |||
| Earnings Growth (Q YOY) | -42.70% | |||
| EPS Diluted (TTM) | -0.05 | |||
| EPS Diluted Growth (Q YOY) | -48.08% | |||
| Balance Sheet | ERGO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 76.10K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 234.30K | |||
| Total Preferred Equity (Q) | 0.00 | |||
| Total Equity (Q) | -1.97M | |||
| Current Ratio (Q) | 0.111 | |||
| Book Value Per Share (Q) | -- | |||
| Total Assets (Q) | -- | |||
| Total Current Liabilities (Q) | 2.11M | |||
| Total Debt (Q) | -- | |||
| Total Liabilities (Q) | -- | |||
| Total Common Equity (Q) | -1.97M | |||
| Cash Flow | ERGO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -7.10K | |||
| Cash from Financing (TTM) | 774.20K | |||
| Net Change in Cash (TTM) | 52.00K | |||
| Levered Free Cash Flow (TTM) | -349.50K | |||
| Cash from Operations (TTM) | -715.10K | |||
